Dan Burgess, Pulmocide CEO
A UK antifungal player with a Big Pharma pedigree bags fresh round of cash as it races toward late-stage trial
The London-based biotech Pulmocide has been pushing its inhaled antifungal toward the clinic for a while now, and early Thursday morning received a new heaping …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
